World Investment Advisors LLC Grows Position in Edwards Lifesciences Co. (NYSE:EW)

World Investment Advisors LLC boosted its stake in Edwards Lifesciences Co. (NYSE:EW) by 1,660.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 72,277 shares of the medical research company’s stock after buying an additional 68,172 shares during the period. World Investment Advisors LLC’s holdings in Edwards Lifesciences were worth $4,770,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of EW. Virtu Financial LLC purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $3,173,000. Teachers Retirement System of The State of Kentucky increased its holdings in Edwards Lifesciences by 43.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 138,755 shares of the medical research company’s stock valued at $9,156,000 after purchasing an additional 42,059 shares during the last quarter. Toronto Dominion Bank raised its position in Edwards Lifesciences by 1.4% in the third quarter. Toronto Dominion Bank now owns 300,280 shares of the medical research company’s stock valued at $19,815,000 after purchasing an additional 4,008 shares during the period. Neo Ivy Capital Management acquired a new position in Edwards Lifesciences during the third quarter worth $726,000. Finally, Coldstream Capital Management Inc. boosted its position in shares of Edwards Lifesciences by 14.9% during the third quarter. Coldstream Capital Management Inc. now owns 9,382 shares of the medical research company’s stock worth $620,000 after buying an additional 1,219 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 35,000 shares of company stock worth $2,323,150 in the last 90 days. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $73.97 on Friday. The stock’s 50-day moving average is $69.26 and its two-hundred day moving average is $74.19. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The firm has a market cap of $43.63 billion, a price-to-earnings ratio of 10.67, a PEG ratio of 3.63 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter last year, the business posted $0.59 EPS. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. Analysts predict that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Analyst Ratings Changes

EW has been the topic of several research reports. JPMorgan Chase & Co. increased their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 11th. UBS Group cut their target price on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 10th. Canaccord Genuity Group boosted their price target on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. Finally, Robert W. Baird reduced their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $78.65.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.